After price deal, Takeda's lung cancer drug Exkivity wins UK green light ahead of J&J rival

In their running battle to treat a rare form of non-small cell lung cancer, Johnson & Johnson got the jump on Takeda in the United States last year. But now Takeda has one-upped J&J in the U.K.